TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07747090: A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of FXS6837 Versus Eculizumab in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 90 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07747090 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07747090 Rescue Dossier →